Enanta Pharmaceuticals ENTA
NASDAQ ENTA
$14.08 +0.06 (+0.43%)
As of: Sep 4, 2026 · 3:59 PM EDT

Enanta Pharmaceuticals (ENTA) EV to EBITDA (2013 - 2026)

Analysis

Enanta Pharmaceuticals (ENTA) EV to EBITDA (2013 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Enanta Pharmaceuticals 409.30 Mn 219.79 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -13.64
Mar 31, 2026 -17.15
Dec 31, 2025 -24.15
Sep 30, 2025 -3.65
Jun 30, 2025 2.25
Mar 31, 2025 3.07
Dec 31, 2024 3.99
Sep 30, 2024 0.96
Jun 30, 2024 -1.85
Mar 31, 2024 -2.12
Dec 31, 2023 3.96
Sep 30, 2023 4.34
Jun 30, 2023 -1.74
Mar 31, 2023 -16.25
Dec 31, 2022 -25.22
Sep 30, 2022 -30.66
Jun 30, 2022 -22.32
Mar 31, 2022 -35.08
Dec 31, 2021 -41.91
Sep 30, 2021 -26.85